Recombinant Human DEFb112 Protein，His

DEFb112 is a recombinant protein that has garnered attention in recent years due to its potential role in the field of immunology and therapeutic development. Originally identified from the defense response of amphibians, particularly the skin secretions of the Xenopus laevis frog, DEFb112 belongs to a family of antimicrobial peptides that exhibit bioactivity against a wide range of pathogens, including bacteria, fungi, and viruses. The increasing prevalence of antibiotic resistance has fueled the search for novel antimicrobial agents, making DEFb112 a focus of research for its unique mechanism of action and ability to modulate immune responses. Studies have demonstrated that DEFb112 not only possesses direct antimicrobial properties but also plays a role in promoting wound healing and modulating inflammation, thus making it a potential candidate for drug development in treating infections and inflammatory conditions. The recombinant expression of DEFb112 in various systems, such as E. coli and yeast, allows for the production of the peptide in a controlled manner for further characterization and evaluation of its therapeutic applications. Ongoing research aims to elucidate the structure-function relationship of DEFb112, optimize its formulation for clinical use, and evaluate its efficacy in preclinical models. The advancement in understanding of DEFb112's properties could lead to innovative strategies in combatting infectious diseases and enhancing immune responses, positioning it as a promising candidate in the realm of modern medicine.